Corcept Therapeutics Incorporated (CORT) Hit a 52 Week High, Can the Run Continue?

Company Performance - Corcept Therapeutics (CORT) shares have increased by 16.2% over the past month and reached a new 52-week high of $62.98 [1] - Year-to-date, the stock has gained 23.6%, outperforming the Zacks Medical sector, which declined by 2.1%, and the Zacks Medical - Drugs industry, which fell by 7.9% [1] Earnings and Revenue - Corcept has consistently exceeded earnings expectations, reporting an EPS of $0.41 against a consensus estimate of $0.27 in its last earnings report on October 30, 2024, and beating revenue estimates by 6.07% [2] - For the current fiscal year, Corcept is projected to earn $1.84 per share on revenues of $689.04 million, with a year-over-year earnings growth of 36.44% [3] - For the next fiscal year, earnings are expected to rise to $2.84 per share on revenues of $777.04 million, reflecting a year-over-year change of 12.77% [3] Valuation Metrics - Corcept's current valuation metrics indicate a premium, trading at 33.8X current fiscal year EPS estimates compared to the peer industry average of 20.7X [6] - On a trailing cash flow basis, the stock trades at 65X versus an average of 8X for its peer group, suggesting it is not positioned in the top echelon from a value perspective [6] Zacks Rank and Style Scores - Corcept holds a Zacks Rank of 2 (Buy) due to favorable earnings estimate revisions from analysts, meeting the criteria for potential gains [7] - The stock has a Value Score of C, a Growth Score of A, and a Momentum Score of C, resulting in a combined VGM Score of B [6][7] Industry Comparison - AMNEAL PHARMACEUTICALS, INC. (AMRX) is a notable peer with a Zacks Rank of 2 (Buy) and strong style scores across Value, Growth, and Momentum [8] - AMRX has also shown strong earnings performance, beating consensus estimates by 23.08% last quarter, with projected earnings of $0.70 per share on revenues of $2.77 billion for the current fiscal year [9] - The Medical - Drugs industry is positioned in the top 35% of all industries, indicating favorable conditions for both CORT and AMRX [10]